SG195309A1 - Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders - Google Patents

Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Info

Publication number
SG195309A1
SG195309A1 SG2013089966A SG2013089966A SG195309A1 SG 195309 A1 SG195309 A1 SG 195309A1 SG 2013089966 A SG2013089966 A SG 2013089966A SG 2013089966 A SG2013089966 A SG 2013089966A SG 195309 A1 SG195309 A1 SG 195309A1
Authority
SG
Singapore
Prior art keywords
indazolyl
crystalline form
glucocorticoid receptor
amide derivatives
receptor mediated
Prior art date
Application number
SG2013089966A
Inventor
Helen Ingemo Andersson
Kelly Yvonne Conway
Michael John Quayle
Original Assignee
Astrazeneca Ab
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Bayer Ip Gmbh filed Critical Astrazeneca Ab
Publication of SG195309A1 publication Critical patent/SG195309A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Crystalline forms of 2,2,2-trifluoro-N-[(lR,2S)-l-[l-(4-fluorophenyl)in- dazol-5-yl]oxy-l-(3-methoxyphenyl)propan-2-yl]acetamide, processes for obtaining them, pharmaceutical intermediates used in their manu¬ facture, pharmaceutical compositions containing them, and their use in medical treatment.
SG2013089966A 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders SG195309A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
SG195309A1 true SG195309A1 (en) 2013-12-30

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013089966A SG195309A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Country Status (16)

Country Link
EP (1) EP2726464A1 (en)
JP (1) JP2014527955A (en)
KR (1) KR20140036230A (en)
CN (1) CN103814015A (en)
AR (1) AR086818A1 (en)
AU (1) AU2012277514A1 (en)
BR (1) BR112013031759A2 (en)
CA (1) CA2839398A1 (en)
IN (1) IN2014MN00023A (en)
MX (1) MX2013014566A (en)
RU (1) RU2013153466A (en)
SG (1) SG195309A1 (en)
TW (1) TW201305115A (en)
UY (1) UY34170A (en)
WO (1) WO2013001294A1 (en)
ZA (1) ZA201309480B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (en) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 Preparation method of (S) -2-chloro-1- (6-fluoro-1-chroman-2-yl) -ethanol
US20230416291A1 (en) * 2020-11-27 2023-12-28 Mirailab Bioscience Inc. HIGH-PURITY ß-NICOTINAMIDE MONONUCLEOTIDE (NMN) AND METHOD FOR PRODUCING SAME
KR102571432B1 (en) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 Composition for treating cancer containing indazolyl ester and amide derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (en) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (en) 1991-04-11 1991-04-11 Astra Ab PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
CN103118726B (en) 2010-07-21 2015-07-22 阿斯利康(瑞典)有限公司 Inhaler
AU2011281318B2 (en) 2010-07-21 2013-09-19 Astrazeneca Ab Inhaler

Also Published As

Publication number Publication date
TW201305115A (en) 2013-02-01
UY34170A (en) 2013-01-31
AR086818A1 (en) 2014-01-22
CA2839398A1 (en) 2013-01-03
AU2012277514A1 (en) 2014-01-09
EP2726464A1 (en) 2014-05-07
JP2014527955A (en) 2014-10-23
MX2013014566A (en) 2014-09-25
ZA201309480B (en) 2015-10-28
CN103814015A (en) 2014-05-21
KR20140036230A (en) 2014-03-25
BR112013031759A2 (en) 2016-12-13
RU2013153466A (en) 2015-08-10
WO2013001294A1 (en) 2013-01-03
IN2014MN00023A (en) 2015-06-12

Similar Documents

Publication Publication Date Title
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
MX2012013628A (en) C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors.
CL2012003604A1 (en) Heterocyclic compounds derived from substituted pyridine carboxamide; Preparation process; pharmaceutical composition; pharmaceutical combination; use in the treatment of cell proliferative disorders, parkinson's disease, cancer, among others.
MX2009009592A (en) Aminopyridines useful as inhibitors of protein kinases.
MX2009006540A (en) Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders.
JO3018B1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
UA109661C2 (en) Pharmaceutical compositions comprising co-crystals of tramadol and celecoxib
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
GEP20156339B (en) New co-crystals of agomelatine, process for their preparation and pharmaceutical compositions containing them
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
CL2011001428A1 (en) Amide derivative compounds of tetrahydroisoquinolyl-4-oxobutyric acid; pharmaceutical composition; and use in the treatment of disorders or diseases mediated by potassium channels kcnq2 / 3, such as pain, epilepsy. urinary incontinence, anxiety, among others.
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
SG195309A1 (en) Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders
HK1197235A1 (en) Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders
MX367327B (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof.
IN2013DN02555A (en)
GEP20156332B (en) Pyrazoles as crth2 antagonists
MX2014000963A (en) Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands.
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
WO2008130319A3 (en) Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain